Cargando…

Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages

Glioma represents the most common primary intracranial malignancy worldwide, with low overall survival rates and limited therapeutic options. The protein CD101, mainly expressed on several immune cells, has been demonstrated to exert potent effects on blunting T cell immune responses across infectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuyang, Yao, Renqi, Shi, Ying, Liu, Yuxiao, Liu, Hongyu, Liu, Jialin, Guan, Yunqian, Yao, Yongming, Chen, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957828/
https://www.ncbi.nlm.nih.gov/pubmed/35350788
http://dx.doi.org/10.3389/fimmu.2022.845223
_version_ 1784676816077717504
author Liu, Yuyang
Yao, Renqi
Shi, Ying
Liu, Yuxiao
Liu, Hongyu
Liu, Jialin
Guan, Yunqian
Yao, Yongming
Chen, Ling
author_facet Liu, Yuyang
Yao, Renqi
Shi, Ying
Liu, Yuxiao
Liu, Hongyu
Liu, Jialin
Guan, Yunqian
Yao, Yongming
Chen, Ling
author_sort Liu, Yuyang
collection PubMed
description Glioma represents the most common primary intracranial malignancy worldwide, with low overall survival rates and limited therapeutic options. The protein CD101, mainly expressed on several immune cells, has been demonstrated to exert potent effects on blunting T cell immune responses across infectious and autoimmunity diseases. Nevertheless, the prognostic value of CD101 expression and its role in the immune microenvironment of various malignancies currently remains elusive. Herein, by adopting bioinformatics methodology, we comprehensively illustrated the potential function and predictive value of CD101 in stratifying clinical prognosis among patients with glioma, for which a high CD101 level predicted an unfavorable clinical outcome in glioma patients. Results from enrichment analyses manifested that CD101 predominantly expressed on the tumor-associated macrophages and was significantly associated with the immune regulatory processes, as evidenced by its positive correlation with immune-related genes and the putative infiltration of immune cells. Evidence provided by in-situ multicolor immunofluorescence staining further validated our findings at the protein level. Taken together, CD101 may serve as a novel biomarker in predicting clinical prognosis and immune status for glioma patients.
format Online
Article
Text
id pubmed-8957828
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89578282022-03-28 Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages Liu, Yuyang Yao, Renqi Shi, Ying Liu, Yuxiao Liu, Hongyu Liu, Jialin Guan, Yunqian Yao, Yongming Chen, Ling Front Immunol Immunology Glioma represents the most common primary intracranial malignancy worldwide, with low overall survival rates and limited therapeutic options. The protein CD101, mainly expressed on several immune cells, has been demonstrated to exert potent effects on blunting T cell immune responses across infectious and autoimmunity diseases. Nevertheless, the prognostic value of CD101 expression and its role in the immune microenvironment of various malignancies currently remains elusive. Herein, by adopting bioinformatics methodology, we comprehensively illustrated the potential function and predictive value of CD101 in stratifying clinical prognosis among patients with glioma, for which a high CD101 level predicted an unfavorable clinical outcome in glioma patients. Results from enrichment analyses manifested that CD101 predominantly expressed on the tumor-associated macrophages and was significantly associated with the immune regulatory processes, as evidenced by its positive correlation with immune-related genes and the putative infiltration of immune cells. Evidence provided by in-situ multicolor immunofluorescence staining further validated our findings at the protein level. Taken together, CD101 may serve as a novel biomarker in predicting clinical prognosis and immune status for glioma patients. Frontiers Media S.A. 2022-03-08 /pmc/articles/PMC8957828/ /pubmed/35350788 http://dx.doi.org/10.3389/fimmu.2022.845223 Text en Copyright © 2022 Liu, Yao, Shi, Liu, Liu, Liu, Guan, Yao and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Liu, Yuyang
Yao, Renqi
Shi, Ying
Liu, Yuxiao
Liu, Hongyu
Liu, Jialin
Guan, Yunqian
Yao, Yongming
Chen, Ling
Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages
title Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages
title_full Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages
title_fullStr Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages
title_full_unstemmed Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages
title_short Identification of CD101 in Glioma: A Novel Prognostic Indicator Expressed on M2 Macrophages
title_sort identification of cd101 in glioma: a novel prognostic indicator expressed on m2 macrophages
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957828/
https://www.ncbi.nlm.nih.gov/pubmed/35350788
http://dx.doi.org/10.3389/fimmu.2022.845223
work_keys_str_mv AT liuyuyang identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages
AT yaorenqi identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages
AT shiying identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages
AT liuyuxiao identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages
AT liuhongyu identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages
AT liujialin identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages
AT guanyunqian identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages
AT yaoyongming identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages
AT chenling identificationofcd101ingliomaanovelprognosticindicatorexpressedonm2macrophages